<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00238849</url>
  </required_header>
  <id_info>
    <org_study_id>OX-03-087</org_study_id>
    <secondary_id>ELVIS II</secondary_id>
    <nct_id>NCT00238849</nct_id>
  </id_info>
  <brief_title>Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.</brief_title>
  <official_title>Phase II Study of Oxaliplatin in Combination With Navelbine for the Second-Line Treatment of Advanced and Metastatic Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Integrated Community Oncology Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Integrated Community Oncology Network</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the response rate to treatment with oxaliplatin and
      Navelbine in patients with previously treated NSCLC. Oxaliplatin and Navelbine have not been
      clinically evaluated yet. However, Navelbine has been safely administered with other platinum
      compounds.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized trial for patients with previously treated Non-small cell lung
      cancer. Each patient will receive 6 cycles of chemotherapy consisting of Oxaliplatin and
      Navelbine. Oxaliplatin is given intravenously every 21 days and Navelbine is administered
      Intravenously on day 1 and day 8 every 21 days.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Previously Treated Metastatic Non-Small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Locally advanced or metastatic non-small cell lung cancer that has recurred,
             progressed, or failed to respond to previous systemic chemo.

          -  Measurable disease

          -  Good performance status (ECOG 0,1 or 2)

        Exclusion Criteria:

          -  Previously treated with Oxaliplatin or Navelbine

          -  Symptomatic CNS metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas A Marsland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Integrated Community Oncology Network</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diane L Edwards, RN,OCN, CCRP</last_name>
    <phone>904-363-7471</phone>
    <email>diane.edwards@foa.cc</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gloria Perez, RN, BSN, CCRP</last_name>
    <phone>904-739-7779</phone>
    <email>gloria.perez@foa.cc</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Integrated Community Oncology Network</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diane Edwards, RN,OCN,CCRP</last_name>
      <phone>904-363-7471</phone>
      <email>diane.edwards@foa.cc</email>
    </contact>
    <contact_backup>
      <last_name>Gloria Perez, RN,BSN,OCN</last_name>
      <phone>904-739-7779</phone>
      <email>gloria.perez@foa.cc</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Integrated Community Oncology Network</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carla Malott, RN</last_name>
      <phone>904-272-3139</phone>
      <email>carla.malott@foa.cc</email>
    </contact>
    <contact_backup>
      <last_name>Joan Ollie, BSN, RN</last_name>
      <phone>904-272-3139</phone>
      <email>joan.ollie@foa.cc</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas A Marsland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linda S Sylvester, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kenneth Goldstein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2005</study_first_submitted>
  <study_first_submitted_qc>October 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2005</study_first_posted>
  <last_update_submitted>October 13, 2005</last_update_submitted>
  <last_update_submitted_qc>October 13, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2005</last_update_posted>
  <keyword>Non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

